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Field cancerization in organ transplant recipients
(OTRs) is a frequent occurrence, setting the stage
for multiple squamous cell carcinomas (SCCs).
Immunosuppression directly promotes keratinocyte
cancer formation and reduces tumor immunity.
Photo damage is amplified in OTRs via several
mechanisms including potentiation of the tumor-
promoting effects of calcineurin inhibitors and anti-
infective medications such as voriconazole. The
challenge with field cancerization in OTRs is to stay
ahead of repetitive epithelial tumor formation. We
present a strategy to treat field cancerization using
ingenol mebutate and discuss other nonregistered
modalities and treatment options.
CASE REPORT
We report the case of a 76-year-old male recipient
of a ABO-incompatible living donor kidney in 2008
for underlying autosomal dominant polycystic kid-
ney disease. He showed significant field cancer-
ization of the skin with large areas of sun damage
and extensive areas of actinic keratosis. These areas
had multiple epithelial tumors that developed over
time. His immunosuppressive medication had been
adjusted to avoid azathioprine, a known ultraviolet
(UV) A photosensitizer and DNA damaging agent,
and to account for his increased incidence of skin
cancer. He currently was maintained on tacrolimus,
1.5 mg orally daily, and mycophenolate mofetil,
500 mg orally daily.
Field cancerization of this patient’s skin has
resulted in 5 SCCs, 2 basal cell carcinomas (BCCs),
multiple SCCs in situ (Bowen’s disease) and actinic
keratoses (AKs) over the last 13 years. The invasivethe Department of Dermatology, University Hospital Zuricha
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titrated up to 25 mg daily was started in 2007 to
reduce his rate of SCC formation. With his immuno-
suppressive medication at low levels and acitretin
chemoprevention at full dosage, we focused on
repeat topical treatments for his field cancerization.
Field treatment on the scalp and face consisted of
various topical modalities including cryotherapy,
imiquimod, and photodynamic therapy (PDT) with
varying success. 5-Flurouracil was not used, as the
patient refused daily application of the cream and
long treatment courses. Because of reduced compli-
ance of our patient in the past and because of his
other chronic illness, we decided for physician-
directed field treatment to ensure application and
efficacy. Ingenol mebutate was considered and used
when other therapies began to fail.
When used, cryotherapy was performed every
3 months on suspicious lesions and led to clinical
remission and regression of treated spots but had no
impact on the larger area of field cancerization. Side
effects included oozing, crusting, inflammation, and
depigmentation of the treated areas. Imiquimod was
used intermittently between 2001 and 2011, bothJAAD Case Reports 2015;1:S19-22.
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Fig 1. Reaction to ingenol mebutate. Field cancerization of the skin was addressed with three
cycles of ingenol mebutate (IM). Here, the third cycle of IM is depicted in an area larger than the
registered 25 cm2. The first day after applying 150 g IM gel showed a pronounced local
reaction with erythema, erosions, and hemorrhagic, yellowish crusting of occiput and vertex
(A), with erythema and erosions of the left temporal fossa triangularis and the left ear (B), as
well of the right temporal fossa (C). Five weeks after stopping the third cycle of 150 g IM gel
the erythema and erosions had improved significantly on occiput and vertex (D), with slight
erythema with no erosions of the left temporal fossa triangularis and the left ear (E) and
atrophied macula with slight erythema and a central superficial erosion of the right temporal
fossa (F). Twenty five weeks after stopping the third cycle of 150 g IM gel, a whitish macule
remained on the vertex with sporadic crusts (G), with complete clinical remission of AK of left
temporal fossa triangularis and the left ear (H), and atrophied macula of right temporal fossa
triangularis (I) without erythema in all treated areas.
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4 weeks inducing erythema, inflammation, and
erosions. Clinically, field cancerization improved in
the treated areas, whereas actinic keratosis tended to
relapse within several months after the last applica-
tion. Because of increasing numbers of intraepithe-
lial lesions and reduced efficacy of self-medicationwith imiquimod, photodynamic therapy was started
in November 2011. Ten cycles of PDT were per-
formed on 5 anatomic areas of the patient’s face and
scalp. Despite clinical improvement, the patient
was unable to tolerate the pain from PDT illumina-
tion, and he refused further PDT therapy in January
2013.
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multiple biopsies of the scalp again confirmed AKs
that required treatment. Radiotherapy, while
commonly used in our department for immunocom-
petent patients to cure large areas such as balding
scalp or face from field cancerization, was not an
option, as our experience shows reduced efficacy
and rapid recurrence of epithelial invasive skin
cancers. PDT would have been a suitable option,
but the patient refused further attempts of PDT
because of pain. Without registered modalities avail-
able in this case, we searched for nonregistered
alternative treatments to improve his field cancer-
ization. Based on previous experience with a limited
number of patients, we chose to apply ingenol
mebutate (IM), 150 g once, as a physician-
directed treatment on a large area of field cancer-
ization, mimicking the application of PDT. A single,
physician-directed application in March 2014
extended the treatment area beyond the registered
protocol of 75 cm2 to a larger area including the
occiput, vertex, temporal fossa triangularis bilater-
ally, and the left ear. A pronounced reaction with
erythema, erosions, and hemorrhagic, yellowish
crusting developed on the next day (Fig 1, A-C ).
Erythema and erosions were present at follow-up
1 month later (Fig 1, D-F ). At the last follow-up in
September 2014, slightly erythematous macules with
few interspersed crusts were present (Fig 1, G-I ). We
observed a full clinical remission of AK with good
cosmetic outcome. The patient never reported any
fever, chills, fatigue or malaise, during or after
ingenol mebutate treatment. C-reactive protein
never exceeded a level of 3.6 mg/L after IM cycles.
Glomerular filtration rate remained at 30 mL/min or
greater after all IM treatment cycles. No other signs of
graft rejection were noted.
DISCUSSION
Actinic keratoses are proliferations of atypical
keratinocytes in the epidermis caused by chronic
UV radiation exposure. The presence of 2 or
more AKs, SCC, or BCC on photo-damaged skin
constitutes the diagnosis of field cancerization and
increases the risk for subsequent invasive nonmela-
noma skin cancer (NMSC).1 Although AKs are
frequent in the general population, OTRs are at
higher risk for AKs because of their exposure to
immunosuppressive medications. These patients
have SCC 65 to 250 times more frequently than those
in the general population.2 The aim in treating AKs is
to prevent the progression to invasive SCC.
Preventive measures involve avoidance of unnec-
essary exposure to UV light and regular use of
sunscreen to prevent or delay the development ofNMSC in OTR.2 Treatment approaches to AKs can be
divided into lesion directed (LD) or field directed
(FD). LD therapies are preferred in patients with few
isolated lesions andwithout elevated risk for invasive
NMSC development. These LD therapies include
local destruction, curettage, cryotherapy, or excision.
FD therapies target clinically visible lesions and
preclinical lesions with keratinocyte changes in the
skin around the visible lesions. Topical treatments
comprise 5-fluorouracil, diclofenac, imiquimod,
topical retinoids, or ingenol mebutate. Other FD
treatment modalities include PDT, radiotherapy,
laser, chemical peels, dermabrasion, or skin grafting.3
Most topical therapies for AKs typically induce
inflammation but must be applied for long periods of
weeks to months. Topical IM has been registered in
the United States and the European Union since
2012. IM is found to have equal efficacy against AK
after only 3 days of application. Furthermore, IM
appears to have a dual mode of action: (1) rapid
necrosis within hours of application and (2) specific
neutrophil-mediated, antibody-dependent cellular
cytotoxicity within days.4 IM gel is available in 2
formulations: 150 g/g used once daily for 3 consec-
utive days to the face or scalp or 500 g/g used once
daily on the trunk or extremities for 2 consecutive
days. Application of IM results in complete cure rates
for the field in the range of 34.1% on trunk and
extremities and 42.2% on the face and scalp
comparing to vehicle in the normal population.
Local skin reactions are the most frequent adverse
events with IM.5 Recent postmarketing reports of
severe allergic reactions and herpes zoster after IM
have led to a label change for IM by the US Food and
Drug Administration. Such inflammatory reactions,
however, can be welcome in the poorly responsive
population of OTR with large areas of field cancer-
ization. We believe that IM may show a similar
benefit with tolerable safety in the population of
OTR at high risk for AK and SCC development.
Previous experience with topical imiquimod, an
immunomodulator, has proven that these substances
are safe in OTR without any indication of damage to
the grafted organ.6 Recently, a US Food and Drug
Administrationeapproved clinical review (Study
number PEP005) of the topical treatment for AKs
with IM 0.05% showed that a 100-cm2 treatment area
is both safe and well tolerated with no increase in
treatment-related adverse events compared with the
treatment areas of 25, 50, or 75 cm2.7 A prospective
trial will address the use of IM and its potential in
OTR starting in 2015. Until then, IM seems a good
second-line choice. Once data on the safety in OTR
are available, IM may well be found suitable for first-
line use in field cancerization.
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lenging, in particular in the heavily affected popula-
tion of OTR. Our case illustrates that IM may be used
on an area larger than registered with an effect
resembling field cancerization treatment by PDT
without eliciting systemic side effects. Although a
multitude of topical treatment modalities are avail-
able for use in this setting, IM can be a useful addition
to the armamentarium available in OTR, in particular
as a physician-directed single application in a large
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